Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with I free seeds by unknown
RESEARCH Open Access
Preimplant factors affecting postimplant CT-
determined prostate volume and the CT/TRUS
volume ratio after transperineal interstitial
prostate brachytherapy with 125I free seeds
Akitomo Sugawara1*, Jun Nakashima2, Etsuo Kunieda3, Hirohiko Nagata4, Hirotaka Asakura5, Mototsugu Oya4,
Naoyuki Shigematsu1
Abstract
Background: The aim was to identify preimplant factors affecting postimplant prostate volume and the increase in
prostate volume after transperineal interstitial prostate brachytherapy with 125I free seeds.
Methods: We reviewed the records of 180 patients who underwent prostate brachytherapy with 125I free seeds for
clinical T1/T2 prostate cancer. Eighty-one (45%) of the 180 patients underwent neoadjuvant hormonal therapy. No
patient received supplemental external beam radiotherapy. Postimplant computed tomography was undertaken,
and postimplant dosimetric analysis was performed. Univariate and multivariate analyses were performed to
identify preimplant factors affecting postimplant prostate volume by computed tomography and the increase in
prostate volume after implantation.
Results: Preimplant prostate volume by transrectal ultrasound, serum prostate-specific antigen, number of needles,
and number of seeds implanted were significantly correlated with postimplant prostate volume by computed
tomography. The increase in prostate volume after implantation was significantly higher in patients with
neoadjuvant hormonal therapy than in those without. Preimplant prostate volume by transrectal ultrasound,
number of needles, and number of seeds implanted were significantly correlated with the increase in prostate
volume after implantation. Stepwise multiple linear regression analysis showed that preimplant prostate volume by
transrectal ultrasound and neoadjuvant hormonal therapy were significant independent factors affecting both
postimplant prostate volume by computed tomography and the increase in prostate volume after implantation.
Conclusions: The results of the present study show that preimplant prostate volume by transrectal ultrasound and
neoadjuvant hormonal therapy are significant preimplant factors affecting both postimplant prostate volume by
computed tomography and the increase in prostate volume after implantation.
Background
As transperineal interstitial prostate brachytherapy
becomes more widely used for early localized prostate can-
cer, there is growing interest in quality assurance measures
that include postimplant dosimetric analysis [1-3]. One
impediment to meaningful dosimetric analysis is unex-
pected prostate volume changes due to seed implantation.
Mechanical trauma, induction of an inflammatory
response, and intraprostatic bleeding are possible mechan-
isms. Prostatic swelling occurs during and after implanta-
tion, and, in general, is the greatest on the day of
operation and the following day. Over time, the prostate
subsequently decreases in size. About one month after
implantation, prostatic swelling is mostly settled. Postim-
plant computed tomography (CT) is recommended at this
time [4]. Sometimes, however, the postimplant prostate
volumes at this time are still larger than the preimplant
volumes, and the degree varies among patients [5-7]. The
variability of volume increase can significantly influence
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the postimplant dosimetric evaluation [8-10]. To our
knowledge, the pathogenesis of the volume change of the
prostate and preimplant factors affecting the increase in
prostate volume after implantation are not well
researched. Identification of the preimplant factors could
be useful in preplanning seed placement to compensate
for the increase. The present study was undertaken to
identify preimplant factors affecting the volume change of
the prostate after transperineal interstitial prostate bra-
chytherapy with 125I free seeds.
Methods
We reviewed the records of 180 patients who underwent
transperineal interstitial prostate brachytherapy with 125I
free seeds for clinical T1/T2 prostate cancer at our insti-
tution. Table 1 details the characteristics of all 180
patients. One hundred thirty-two (73.3%) patients had a
Gleason score of 6 or less and 48 (26.7%) patients had a
Gleason score of 7. The mean ± standard error (SE)
prostate-specific antigen (PSA) level was 7.06 ± 0.23 ng/
mL (range, 4.01-19.88 ng/mL). Eighty-one (45%) of the
180 patients underwent 5.1 ± 0.3 months of neoadjuvant
hormonal therapy (NHT), which consisted of luteinizing
hormone-releasing hormone agonist and antiandrogens.
NHT was generally undertaken in patients with a pros-
tate volume >40 cc or those with pubic arch interfer-
ence at the preimplant volume study by transrectal
ultrasound (TRUS) [11]. Hormonal therapy was not
continued past the date of implant.
A preplan was obtained using TRUS images taken at 5
mm intervals from the base to the apex of the prostate
with the patient in the dorsal lithotomy position at one
month before implantation. The prostatic contours were
outlined by a single radiation oncologist (AS). The plan-
ning target volume included the prostate gland, with a
margin of 3 mm anteriorly and laterally and 5 mm in
the cranial and caudal directions. No margin was added
posteriorly at the rectal interface. Treatment planning
used a peripheral or a modified peripheral approach.
The prescribed dose to the planning target volume
(prostate with margin) was 145 Gy. Preplan dosimetry
aimed for a prostate V100 (% of the prostate volume
receiving the prescribed dose or greater) of >99%, a
prostate D90 (dose to 90% of the prostate) of 120% to
125% of the prescribed dose, a prostate V150 of 55% to
60%, a urethra V100 (% of the urethral volume receiving
the prescribed dose or greater) of >99%, a urethra V150
of 0%, and a rectum V100 (cc of the rectum volume
receiving the prescribed dose or greater) of < 1.3cc, and
a rectum V150 of 0cc. During preplanning with TRUS
and seed implantation, the urethra was identified with
aerated gel for ease of visualization. An attempt was
made during the manual planning to place seeds into
the prostate, not to place seeds within 0.5 cm of the
urethra. VariSeed 7.1 (Varian Medical Systems, Palo
Alto, CA) was used both in planning and in calculation
of the final dosimetry. TG 43 formalism was used in the
preplanning and postimplant dosimetry analyses [12].
All 180 patients were treated with 125I radioactive free
seeds with a Mick applicator (Mick Radio-Nuclear
Instruments, Bronx, NY). The radioactive seeds were
inserted according to the preplan, under TRUS and
fluoroscopic guidance. No supplemental external beam
radiotherapy was used. Postimplant axial CT images of
the prostate at 2.5 to 3.0-mm intervals with patients in
the supine position were obtained at a mean ± SE of 7.6
± 0.2 weeks after implantation. The prostatic contours
were outlined by a single radiation oncologist (AS). The
postimplant prostatic margins were similar to preplan
margins. Postimplant dosimetry calculations were per-
formed. The following information was recorded: patient
characteristics, preimplant prostate volume by TRUS,
postimplant prostate volume by CT, and postimplant
CT scan volume relative to the ratio of the preimplant
TRUS volume of the prostate (CT/TRUS volume ratio).
Statistical analysis
Data are presented as mean ± SE. Pearson correlation
coefficients were used to examine the relationship
between postimplant prostate volume by CT and contin-
uous variables and that between the CT/TRUS volume
ratio and continuous variables. Associations between
categorical variables were assessed with Fisher’s exact
test. Student’s t-test was used for quantitative data. The
significance level was p < 0.05.
Stepwise multiple linear regression analyses were per-
formed to estimate postimplant prostate volume by CT
and the CT/TRUS volume ratio from age, serum PSA,
NHT, preimplant prostate volume by TRUS, number of
needles, and number of seeds implanted.
Results
The mean ± SE preimplant and postimplant D90 were
176.6 ± 1.0 Gy and 171.4 ± 1.5 Gy, respectively. The
Table 1 Patient characteristics (N = 180)
Variable Range
Age (y) 68.7 ± 0.5 (53-80)
Initial PSA (ng/mL) 7.06 ± 0.23 (4.01-19.88)
NHT (+), n (%) 81 (45.0%)
NHT (-), n (%) 99 (55.0%)
Preimplant prostate volume by TRUS (cc) 22.9 ± 0.5 (10.1-41.0)
Total radioactivity (mCi) 23.5 ± 0.3 (13.1-33.6)
Number of seeds implanted 70.9 ± 0.9 (40-100)
Number of needles 25.0 ± 0.4 (12-39)
Data are presented as mean ± standard error (range) or number (percent) of
patients. Abbreviations: PSA = prostate-specific antigen; NHT = neoadjuvant
hormonal therapy; TRUS = transrectal ultrasound.
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mean ± SE preimplant and postimplant V100 were 97.2 ±
0.2% and 95.4 ± 0.3%, respectively. The mean ± SE post-
implant prostate volume by CT was 26.0 ± 0.5 cc (range,
10.8 - 51.0 cc). Postimplant prostate volume by CT was
not significantly different between patients with NHT
and those without (25.9cc vs. 26.1cc, p = 0.769). The
mean ± SE postimplant D90 in patients with NHT and
those without were 166.5 ± 1.9Gy (range, 123.3 -
223.0Gy) and 175.4 ± 2.2Gy (range, 125.9 - 223.6Gy),
respectively. The mean ± SE postimplant V100 in
patients with NHT and those without were 94.9 ± 0.4%
(range, 76.5 - 99.9%) and 95.8 ± 0.4% (range, 83.2 -
100.0%), respectively. The mean ± SE number of seeds
implanted in patients with NHT and those without were
67.2 ± 1.3 (range, 40 - 95) vs. 73.9 ± 1.2 (range, 45 - 100),
respectively. The mean ± SE number of needles in
patients with NHT and those without were 22.6 ± 0.6
(range, 12 - 37) vs. 26.9 ± 0.5 (range, 15 - 39), respec-
tively. Preimplant prostate volume by TRUS (r = 0.802,
p < 0.001), serum PSA (r = 0.159, p = 0.034), number of
needles (r = 0.582, p < 0.001), and number of seeds
implanted (r = 0.760, p < 0.001) were significantly and
positively correlated with postimplant prostate volume by
CT.
Stepwise multiple linear regression analysis showed
that preimplant prostate volume by TRUS and NHT
were significant independent factors affecting postim-
plant prostate volume by CT (Table 2). The predictive
equation for postimplant prostate volume by CT (cc)
was as follows: V = a1 + a2Vp +a3x, where V = postim-
plant prostate volume, Vp = preimplant prostate volume
by TRUS and x = 1 or 0 for with or without NHT. The
values of a1, a2 and a3 were 3.390, 0.899, and 4.427,
respectively. Figure 1 shows the plot of the postimplant
CT vs. the preimplant TRUS volume of the prostate for
patients with NHT and those without.
The mean ± SE CT/TRUS volume ratio was 1.16 ±
0.01 (range, 0.80 - 1.74). The CT/TRUS volume ratio
was significantly higher in patients with NHT than in
those without (1.30 vs. 1.05, p < 0.001). Preimplant
prostate volume by TRUS (r = -0.538, p < 0.001), num-
ber of needles (r = -0.505, p < 0.001), and number of
seeds implanted (r = -0.408, p < 0.001) were significantly
and negatively correlated with the CT/TRUS volume
ratio.
Stepwise multiple linear regression analysis showed
that preimplant prostate volume by TRUS and NHT
were significant independent factors affecting the CT/
TRUS volume ratio (Table 3). The predictive equation
of the CT/TRUS volume ratio was as follows: the CT/
TRUS volume ratio = b1 + b2Vp + b3×, where Vp =
preimplant prostate volume by TRUS and × = 1 or 0 for
with or without NHT. The values of b1, b2 and b3 were
1.303, - 0.010, and 0.204, respectively. Figure 2 shows
the plot of the CT/TRUS volume ratio vs. the preim-
plant prostate volume by TRUS for patients with NHT
and those without.
Discussion
The purpose of the present study was to identify preim-
plant factors affecting postimplant CT-determined
Table 2 Multivariate analysis: stepwise multiple linear
regression model for postimplant prostate volume by CT
Covariate B SE p value
Constant 3.390 1.031 0.001
Preimplant prostate volume by TRUS (cc) 0.899 0.039 < 0.001
NHT 4.427 0.503 < 0.001
Abbreviations: CT = computed tomography; B: unstandardized coefficients; SE:
standard errors of unstandardized coefficients; TRUS = transrectal ultrasound;
NHT = neoadjuvant hormonal therapy.
Figure 1 Postimplant CT vs. preimplant TRUS volume of the
prostate for patients with NHT (black circle) and those without
(blank circle). Data are shown for all 180 patients. Abbreviations: CT
= computed tomography; TRUS = transrectal ultrasound; NHT =
neoadjuvant hormonal therapy.
Table 3 Multivariate analysis: stepwise multiple linear
regression model for the CT/TRUS volume ratio
Covariate B SE p value
Constant 1.303 0.047 < 0.001
Preimplant prostate volume by TRUS (cc) -0.010 0.002 < 0.001
NHT 0.204 0.023 < 0.001
Abbreviations: CT = computed tomography; TRUS = transrectal ultrasound; CT/
TRUS volume ratio = postimplant CT scan volume relative to the ratio of the
preimplant TRUS volume of the prostate; B: unstandardized coefficients; SE:
standard errors of unstandardized coefficients; NHT = neoadjuvant hormonal
therapy.
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prostate volume and the CT/TRUS volume ratio in
prostate cancer patients treated with transperineal inter-
stitial prostate brachytherapy with 125I free seeds. The
results showed that preimplant prostate volume by
TRUS and NHT are significant independent factors
affecting both postimplant prostate volume by CT and
the CT/TRUS volume ratio. From these results, we have
developed regression equations to predict postimplant
prostate volume by CT and the CT/TRUS volume ratio.
NHT was revealed to be a significant preimplant fac-
tor affecting both postimplant prostate volume by CT
and the increase in prostate volume after implantation.
The present results indicate that a patient with NHT
has a higher CT/TRUS volume ratio than a patient
without. These results are in agreement with a previous
report [13]. Ash and coworkers reported that the mean
CT/TRUS volume ratio was 1.17 for patients with NHT
vs. 0.98 for those without (p < 0.001) [13]. This means
that patients with NHT have a greater increase in pros-
tate volume after implantation. The reason why NHT is
positively associated with the increase in prostate
volume after implantation is unclear. It has been
reported that NHT is associated with an increased risk
of acute urinary morbidity after implantation [14-17].
The association of NHT with the increase in prostate
volume would provide an explanation for this clinical
observation, however, it does not explain the
pathophysiology of the increased tendency to prostate
swellings. This issue needs to be explored in further
studies.
The present results, however, may seem to contradict
those of some other studies [18-20]. Badiozamani and
colleagues reported that NHT had no consistent effect
on postimplant volume changes [18]. Tanaka and collea-
gues reported that no predictive factors for edema were
found, including NHT [20]. Potters and colleagues
reported that the CT/TRUS volume ratio was signifi-
cantly lower for patients treated with NHT [19]. The
discrepancies could be attributed to differences in the
timing of postimplant CT scans among these studies. In
the studies by Badiozamani and colleagues and Tanaka
and colleagues, the postimplant CT scans were obtained
the day after implantation, when prostatic swelling was
the greatest. In the study by Potters and colleagues, they
were obtained 1.6-6.5 weeks (median, 3.1 weeks) after
implantation, which seems somewhat early for all of the
prostatic edema to resolve, whereas, in the study by Ash
and coworkers, they were obtained 6-8 weeks after
implantation, when the swelling had resolved [8,19].
These findings suggest that the impact of NHT on post-
implant prostate volume changes differs depending on
the timing of the postimplant CT scans. In the present
study, the postimplant CT scans were obtained at a
mean of 7.6 weeks after implantation, which is similar
to the study of Ash and coworkers. Consequently, it is
considered that the results of the present study are con-
sistent with those by Ash and coworkers, showing a
positive association between the CT/TRUS volume ratio
and NHT. However, further study will be needed to
assess the potential impact of NHT on the increase in
prostate volume after implantation.
The next factor affecting postimplant prostate volume
by CT and the increase in prostate volume after implanta-
tion is preimplant prostate volume by TRUS. In univariate
and multivariate analyses, preimplant prostate volume by
TRUS was associated significantly with postimplant pros-
tate volume by CT and the CT/TRUS volume ratio. The
present results indicate that a patient with a smaller gland
has a higher CT/TRUS volume ratio. This is consistent
with a previous report [21]. Pinkawa and colleagues
reported that preimplant prostate volume was correlated
with the extent of postimplant edema both on day 1 and
day 30, indicating that smaller prostates developed greater
edema [21]. However, some previous reports are inconsis-
tent with the present study [6,18]. Badiozamani and collea-
gues reported that no single parameter, including
preimplant prostate volume, could accurately predict the
degree of swelling on day 1 [18]. Moreover, Taussky and
colleagues reported in their study consisting of only 20
patients that, although preimplant prostate volume was
associated with the CT/TRUS volume ratio on Day 1, it
Figure 2 The CT/TRUS volume ratio vs. preimplant prostate
volume by TRUS for patients with NHT (black circle) and those
without (blank circle). Data are shown for all 180 patients.
Abbreviations: CT = computed tomography; TRUS = transrectal
ultrasound; the CT/TRUS volume ratio = the postimplant CT scan
volume relative to the ratio of the preimplant TRUS volume of the
prostate; NHT = neoadjuvant hormonal therapy.
Sugawara et al. Radiation Oncology 2010, 5:86
http://www.ro-journal.com/content/5/1/86
Page 4 of 6
was not associated with the CT/TRUS volume ratio on
Day 30 [6]. These discrepancies are due to the different
timings of postimplant CT scans and the small numbers
of patients in their studies. Further study will be needed to
assess the potential impact of preimplant prostate volume
on the volume increases after implantation.
Although the CT/TRUS volume ratio is important
because it affects postimplant dosimetric results, it has not
been fully determined what the optimal cut-off value of
the CT/TRUS volume ratio should be for predicting sub-
optimal dosimetry. Few investigators have determined a
cut-off value of the CT/TRUS volume ratio for predicting
suboptimal dosimetry [19]. Potters and colleagues
reported that a CT/TRUS volume ratio >1.5 was an inde-
pendent predictor of poor D90 dose [19]. It is, however,
difficult to compare their results directly to ours. The rea-
sons are as follows. First, the results of Potters and collea-
gues showed a relatively higher CT/TRUS volume ratio
(mean, 1.43), due to the early timing of postimplant CT
scans. On the contrary, the results of the present study
showed the mean CT/TRUS volume ratio of 1.16, which is
in agreement with those of many other studies
[6,7,13,19,22,23]. Second, in the Cox regression analysis of
Potters and colleagues, which was performed to identify
independent factors predictive of poor D90 dose, patients
with NHT were excluded [19]. Therefore, the cut-off value
presented by Potters and colleagues could not be applied
directly to the present data. An optimal cut-off value of
the CT/TRUS volume ratio to predict suboptimal dosime-
try will need to be explored in further studies.
The results of the present study show that in patients
who had a smaller prostate gland and/or who under-
went NHT, a greater increase in prostate volume is pre-
dicted after brachytherapy, which may affect
postimplant dosimetric results. For these patients, to
achieve optimal dose coverage of the prostate, it is
thought to be useful to implant more seeds than
expected. However, this speculation should be validated
in future investigations.
Conclusions
The results of the present study show that NHT and
preimplant prostate volume by TRUS are significant
preimplant factors affecting both postimplant prostate
volume by CT and the CT/TRUS volume ratio. Thus,
the combination of these two factors can be used to
predict postimplant prostate volume by CT and the CT/
TRUS volume ratio in prostate cancer patients treated
with transperineal interstitial prostate brachytherapy
with 125I free seeds.
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